Allosteric modulators and selective agonists of muscarinic receptors
- PMID: 17192667
- DOI: 10.1385/JMN:30:1:165
Allosteric modulators and selective agonists of muscarinic receptors
Abstract
Allosteric modulators of ligand-receptor interactions are found for a variety of receptors (Christopoulos, 2002). Allosteric agents attach to a binding site being topographically distinct from the site for conventional (orthosteric) agonists or antagonists. In the case of the muscarinic receptor, a huge selection of structurally divergent modulators has been described for different receptor subtypes (Mohr et al., 2003). Alkane-bisammonio-type compounds carrying lateral phthalimido substituents are known to have a high affinity for the common allosteric binding site of the muscarinic acetylcholine M2 receptor (mAChR M2), which is already occupied by the orthosteric antagonist N-methylscopolamine (NMS). The resulting allosteric inhibition of the dissociation of [3H]NMS from the M2 receptors in porcine cardiac homogenates served to indicate binding of the test compounds to the allosteric site. Additionally, allosteric modulators can strongly influence equilibrium binding of the orthosteric ligand: Its binding can be reduced, left unaltered or elevated, and encoded as negative, neutral, and positive cooperativity, respectively (Christopoulos and Kenakin, 2002). The cooperativity is strongly dependent on the pair of allosteric/orthosteric ligands and on the receptor subtype.
Similar articles
-
Allosteric site in M2 acetylcholine receptors: evidence for a major conformational change upon binding of an orthosteric agonist instead of an antagonist.Naunyn Schmiedebergs Arch Pharmacol. 2006 Jan;372(4):267-76. doi: 10.1007/s00210-005-0023-4. Epub 2005 Dec 16. Naunyn Schmiedebergs Arch Pharmacol. 2006. PMID: 16362429
-
Identification of a [3H]Ligand for the common allosteric site of muscarinic acetylcholine M2 receptors.Mol Pharmacol. 1998 Jul;54(1):139-45. doi: 10.1124/mol.54.1.139. Mol Pharmacol. 1998. PMID: 9658199
-
M2 receptor binding of the selective antagonist AF-DX 384: possible involvement of the common allosteric site.Mol Pharmacol. 1998 Feb;53(2):304-12. doi: 10.1124/mol.53.2.304. Mol Pharmacol. 1998. PMID: 9463489
-
Allosteric interactions at muscarinic cholinoceptors.Clin Exp Pharmacol Physiol. 1998 Mar-Apr;25(3-4):185-94. doi: 10.1111/j.1440-1681.1998.t01-4-.x. Clin Exp Pharmacol Physiol. 1998. PMID: 9590567 Review.
-
Ligands for the common allosteric site of acetylcholine M2-receptors: development and application.Pharm Acta Helv. 2000 Mar;74(2-3):149-55. doi: 10.1016/s0031-6865(99)00028-x. Pharm Acta Helv. 2000. PMID: 10812952 Review.
Cited by
-
Heterodimerization of Dibenzodiazepinone-Type Muscarinic Acetylcholine Receptor Ligands Leads to Increased M2R Affinity and Selectivity.ACS Omega. 2017 Oct 31;2(10):6741-6754. doi: 10.1021/acsomega.7b01085. Epub 2017 Oct 16. ACS Omega. 2017. PMID: 30023530 Free PMC article.
-
Bitopic ligands: all-in-one orthosteric and allosteric.F1000 Biol Rep. 2009 Oct 14;1:77. doi: 10.3410/B1-77. F1000 Biol Rep. 2009. PMID: 20948611 Free PMC article.
-
Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts.J Med Chem. 2019 Jan 10;62(1):88-127. doi: 10.1021/acs.jmedchem.8b00875. Epub 2018 Aug 28. J Med Chem. 2019. PMID: 30106578 Free PMC article. Review.
-
In vivo investigations on the cholinesterase-inhibiting effects of tricyclic quinazolinimines: scopolamine-induced cognitive impairments in rats are attenuated at low dosage and reinforced at higher dosage.Pflugers Arch. 2008 Feb;455(5):895-901. doi: 10.1007/s00424-007-0325-0. Epub 2007 Aug 24. Pflugers Arch. 2008. PMID: 17717685
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources